Feasibility of Ambulatory Talc. Pleurodesis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDavid Rollins

About this trial

Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this patient group. Our study would investigate whether this treatment could be provided on an outpatient, ambulatory basis and facilitate a greater quality of life.

The investigators would assess deliverability of the trial protocol and collect patient feedback to see if our patients consider it an acceptable and worthwhile intervention.

Eligibility criteria

Qualifiers

Malignant pleural effusion

Life expectancy >30 days

WHO PS 1-2 (3 if due to dyspnoea)

Disqualifiers

Previous failed pleurodesis (on affected side)

Known non-expansile lung

Trial design

Treatments tested in this trial

  • ambulatory chest drain and talc pleurodesis

Treatment groups

15 Participants
are divided into 1 treatment group

Sponsors and collaborators

David Rollins

Lead sponsor

North Tees and Hartlepool NHS Foundation Trust

Sponsor institution